At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Jim Routt
Advertisement
Vice President and Unit Head, Oncology Global Therapeutic Delivery, IQVIA
Articles by Jim Routt
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
2
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
3
Reducing Site Burden Through Better Technology Integration in Clinical Trials
4
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
